Go To Global Site
Welcome to UCB in the United States

Oct

30

Patients Inspiring Growth at UCB's Bedford Lab

UCB researchers like Jessica Williamson, PhD, come to work driven by a singular purpose – to create value for people living with severe disease. That’s because patients depend on the important work of scientific research to discover new medical innovations that will help them achieve their goals. Read more from Dr. Williamson about why she's passionate about innovating for patients and UCB's growing research presence in the greater Boston area.

Oct

21

Infographic: Seizure Clusters

At UCB, we keep patients at the center - inspiring us, driving our scientific discovery, and leading us to rethink the patient experience. We have a rich heritage in epilepsy, and today, we’re shining a spotlight on seizure clusters, which can affect people with uncontrolled epilepsy, to help spread awareness. Check out the full infographic below.

Oct

21

Disease Spotlight: Seizure Clusters

At UCB, we keep patients at the center - inspiring us, driving our scientific discovery, and leading us to rethink the patient experience. We have a rich heritage in epilepsy, and today, we’re shining a spotlight on seizure clusters, which can affect people with uncontrolled epilepsy, to help spread awareness.

Oct

17

Bimekizumab Phase 3 Psoriasis Study Meets All Endpoints, Achieving Significantly Greater Efficacy Versus Placebo and Ustekinumab

• The Phase 3 BE VIVID study evaluating the efficacy and safety of bimekizumab in adults with moderate-to-severe chronic plaque psoriasis met all primary and ranked secondary endpointsi

Oct

15

Finding the Inspiration to Thrive with nr-axSpA

Learn more about living with non-radiographic axial spondyloarthritis (nr-axSpA) from Chelsea, who recently shared her story.

Oct

10

UCB agrees to acquire Ra Pharmaceuticals: Joining forces to improve treatment options for people living with myasthenia gravis and other rare diseases

• Will enhance UCB’s leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB’s rozanolixizumab, an FcRn targeting antibody also in phase 3

Oct

09

It’s Time to Come Together to Deliver More for Patients

At UCB, we keep patients at the center of everything we do, inspiring us, driving our scientific discovery, and leading us to rethink the patient experience. Read more from UCB's CEO and Chairman of the Executive Committee, Jean-Christophe Tellier, about why it's time to come together across all healthcare stakeholders to deliver more for patients.

Oct

03

UCB PharmD Fellows Have a Big Impact on Patients

UCB Global Regulatory Affairs Fellows (L to R): Howraa Alasker, PharmD and Tanya Chaudhri, PharmD, RPh

The 2020-2022 UCB Global Regulatory Affairs (GRA) PharmD Fellowship Program, a collaboration with the Industry Pharmacists Organization (IPhO), is a 2-year rotational program located at UCB’s Atlanta campus aimed at growing top regulatory talent for the future. Established in 2017, the Fellowship Program is designed to provide PharmD graduates with the opportunity to learn and experience all aspects of regulatory affairs under the mentorship of experienced preceptors. Applications are being accepted now until November 1, 2019. Learn more about the fellowship from current fellow, Tanya Chaudhri, PharmD, RPh.

Oct

02

Putting My Passion into Action: Discovering and Advancing Immunology Treatments

As a clinician and researcher, Dr. Victor Sloan is passionate about caring for people living with rheumatic diseases. Read about how he's putting his passion into action by helping to discover and deliver innovative therapies for patients living with non-radiographic axial spondyloarthritis (nr-axSpA).